Part of a three volume series. Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections.
This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been a factor. These are part of the factors that have lead to nearly 6-billion dollar antifungal drug industry.
Anti-Infectives, Second Edition, Volume I: Antifungals is a comprehensive review of the market for anti fungal drugs. This is the first volume of Kalorama Information’s 2nd edition of its popular three-part series on anti-infective markets. The report focuses on two segments of antifungal treatment: systemic and topical. The report covers both currently marketed and late stage development antifungal products in detail.
For both the systemic and topical antifungal markets, this report includes:
U.S. and World Revenues
Forecasts to 2011.
Overview and Incidence Data
Description of Products on the Market
Review of Products in Development
Competitive Analysis of Leading Providers.
10 Key Issues and Trends facing the antifungal industry
Revenues for each segment were generated using dollar and unit sales for each product. All market data pertain to the world market at the manufacturers’ level. Revenues and market share of major brands such as Lamisil, Diflucan, Sporanox, Cancidas, Vfend, and others are included.
Competitive analysis is provided for the year 2006. The forecasted market analysis for 2004-2011 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.
As part of Kalorama's trusted information-gathering process, the information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information and developing forecasts.
For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
Table of Contents
CHAPTER ONE: Executive Summary
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: Introduction
Overview
Introduction to Pathogens
Antimicrobial Spectrum
Bacterial Resistance
Principles of Anti-infective Therapy
Infecting Organism
Antibiotic Sensitivity Testing
Site of Infection
Host Defenses and Organ Function
Antibiotic Pharmcokinetics
Monitoring Therapy
Combination Therapy and Prophylactic Use
Fungal Infections
Types of Fungal Infections
Superficial
Systemic
Histoplasmosis
Coccidioidomycosis
Blastomycosis
Demographics and Statistics
CHAPTER THREE: Systemic Antifungal Drugs
Overview
Description of Products
Allylamines
Terbinafine (Lamisil - Novartis)
Azoles
Fluconazole (Diflucan - Pfizer)
Ketoconazole (Nizoral, Johnson & Johnson)
Miconazole (Monistat, Johnson & Johnson)
Itraconazole (Sporanox, Johnson & Johnson)
Posaconazole (Noxafil, Schering-Plough)
Virconazole (Vfend, Pfizer)
Polyene Macrolides
Amphotericin B (Ambisome, Astellas; Abelcet, Enzon; Fungizone, Apothecon).
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
